| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 12 Nov 2026 | Form 4 |
| 12 Nov 2026 |
Form 4: Francis Richard D, President and CEO
Sold 250,000 shares ($10.6M) |
| 12 Nov 2026 |
Form 4: Sabag Mark, See "Remarks"
Received 44,710 shares by exercise or conversion ($1.56M) · Sold 44,710 shares ($1.97M) |
| 12 Nov 2026 |
Form 4: Weiss Amir, Chief Accounting Officer
Received 7,755 shares by exercise or conversion ($269K) · Sold 17,289 shares ($744K) |
| 12 Nov 2026 | Form 4 |
| 12 Nov 2026 |
Form 4: Brailer David J, Director
Granted 3,326 Restricted Share Units |
| 12 Nov 2026 |
Form 3: Brailer David J, Director
No securities owned |
| 12 Nov 2026 | 144 |
| 12 Nov 2026 | 144 |
| 10 Nov 2026 | 144 |
| 10 Nov 2026 | SCHEDULE 13G/A |
| 09 Nov 2026 | 144 |
| 06 Nov 2026 |
Form 4: Sabag Mark, See "Remarks"
Received 46,000 shares by exercise or conversion ($1.61M) · Sold 46,000 shares ($1.93M) |
| 06 Nov 2026 |
Form 4: Bergwerk Dov, Interim Cheif Legal Officer
Received 26,260 shares by exercise or conversion ($861K) · Sold 26,260 shares ($1.1M) |
| 05 Nov 2026 | 144 |
| 04 Nov 2026 | 144 |
| 03 Nov 2026 | 10-Q |
| 03 Nov 2026 |
8-K: Results of Operations and Financial Condition
Teva’s Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative Brands; Raises 2026 Outlook for AUSTEDO®, AJOVY® and UZEDY®; Delivers Substantial Gross Margin Expansion |
| 02 Nov 2026 | SCHEDULE 13G/A |
Loading...